David Rosa Sells 24,500 Shares of Intuitive Surgical (NASDAQ:ISRG) Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) CEO David Rosa sold 24,500 shares of the company’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $547.55, for a total value of $13,414,975.00. Following the completion of the transaction, the chief executive officer owned 234,256 shares in the company, valued at $128,266,872.80. This represents a 9.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Intuitive Surgical Stock Down 1.1%

Shares of NASDAQ ISRG opened at $545.39 on Wednesday. The firm has a market capitalization of $195.51 billion, a P/E ratio of 72.14, a P/E/G ratio of 5.07 and a beta of 1.61. The stock’s 50-day simple moving average is $460.82 and its two-hundred day simple moving average is $497.70. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.41. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.The business had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period in the prior year, the company earned $1.84 EPS. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Institutional Trading of Intuitive Surgical

Several large investors have recently modified their holdings of ISRG. Norges Bank bought a new stake in shares of Intuitive Surgical in the second quarter worth $2,569,260,000. Nuveen LLC bought a new stake in shares of Intuitive Surgical in the first quarter worth $1,715,899,000. Vanguard Group Inc. grew its holdings in shares of Intuitive Surgical by 2.1% in the second quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock worth $18,115,025,000 after acquiring an additional 670,302 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Intuitive Surgical by 26.1% in the first quarter. Goldman Sachs Group Inc. now owns 2,819,666 shares of the medical equipment provider’s stock worth $1,396,496,000 after acquiring an additional 584,375 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Intuitive Surgical by 20.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,393,951 shares of the medical equipment provider’s stock worth $1,680,922,000 after acquiring an additional 566,979 shares during the period. Institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

ISRG has been the subject of a number of research analyst reports. Zacks Research upgraded Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 24th. Erste Group Bank restated a “hold” rating on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Jefferies Financial Group raised their target price on Intuitive Surgical from $550.00 to $560.00 and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Royal Bank Of Canada set a $625.00 target price on Intuitive Surgical and gave the company an “outperform” rating in a research note on Wednesday, October 22nd. Finally, UBS Group set a $600.00 target price on Intuitive Surgical and gave the company a “neutral” rating in a research note on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $608.92.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.